GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate the development and manufacture of cell and gene therapies.
The core objective of the collaboration is to make the therapies affordable and accessible to patients.
The companies will offer a comprehensive suite of cell therapy services to biotech, pharmaceutical and government entities, and to hospitals.
These solutions will help drug developers address the challenges of regulatory compliance, production scalability, quality assurance and cost-effectiveness.
The partnership’s initial focus is to support drug developers to advance cell and gene therapies (CGT) using pioneering modalities including viral vectors (AAV, LVV, RV and HSV), antibodies (mAb, bsAb and ADC), CAR-T therapies and vaccines (DNA, mRNA and protein).
The new CGTs treat a broad range of indications including rare diseases, immune disorders and blood cancers.
GenScript ProBio will gain access to CCS’s knowledge in clinical cell therapy manufacture and bone marrow transplant services, blood-related products, analytical testing, fill/finish, process development and optimisation, apheresis and cell sourcing, and cryopreservation.
CCS will use the extensive capabilities of GenScript ProBio in the development and manufacture of viral vectors, antibody-drug conjugates, antibody/protein drugs, plasmids, vaccines and mRNA.
GenScript ProBio board of directors chairman Patrick Liu stated: “Joining forces with the New York Blood Center’s Comprehensive Cell Solutions allows us to harness the combined experience and capabilities of both entities to propel innovation and uphold excellence within the cell therapy sector.
“Our mutual dedication to quality, safety and efficiency will expedite the development and commercialisation of novel cell therapy treatments for patients.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.